TP53 and psoriasis: The results have typically been interpreted in the context of exposure to various systemic treatments, with a focus on 8-methoxypsoralen plus ultraviolet A (PUVA) therapy, which can cause p53 mutations and promote the emergence of NMSC in psoriasis patients [34].